US/UK/Canada

Share

Pick a time period -
Tags ( Active)

In the starting blocks for heart preservation and PrimECC trial

SECOND QUARTER 2020 (APRIL-JUNE) Financial information · Net sales of non-durable goods in the quarter amounted to SEK 28.0 (50.5) million, corresponding to a decrease of 44 percent in SEK and 46 percent in local currency. Total net sales (incl. durable goods) in the quarter amounted to SEK 30.4 (56.4) million, corresponding to a decrease of 46 percent in SEK and 47 percent in local currency. The Covid-19 pandemic has had a large impact on the sales and product mix during the quarter. The Covid-19 pandemic has resulted in a decrease of lung transplants since intensive Care units

Conference call on Interim Report

Invitation to attend XVIVO Perfusion’s conference call regarding the presentation of the interim report April - June 2020. The presentation will be held in English.Time: Friday, July 10, 2020 at 2.00 p.m. CET Information regarding the conference can be found under the following link:https://onlinexperiences.com/Launch/QReg/ShowUUID=4942D3FE-A7DD-4260-92DB-B2391D5B83D2 Phone numbers to the conference:Sweden dial in number: +46 856 642 651USA dial in number: +1 631 913 1422International (UK) dial in number: +44 (0)3333 000 804Conference name: XVIVO Perfusion, Conference ID:

The study from Lund published in Nature Communications

According to  an article published today in the scientific journal Nature Communications, the use of the heart preservation technology developed  by Professor Stig Steen  is a safe method of preservation of hearts. This is an important step for XVIVO as well as, since the company's heart preservation products are based on this technology. The commercial rights to the technology are owned by XVIVO.Today the first scientific article was published which describes the results after storage during the transport of donated hearts using the method developed by Professor Stig Steen in Lund, and to

Redeye: Xvivo Perfusion - Well-preserved value

Redeye re-initiates coverage of Xvivo with strengthened conviction following a deep dive into its clinical data and that of key competitor TransMedics, as well as target markets. While the coronavirus crisis presents some nearer-term challenges, the case is attractive in view of Xvivo’s commercial and clinical progress, strong positioning for a surgical pick-up and undemanding valuation even after the share’s recent rebound. Read more and download the research update: https://bit.ly/36FMHNa   Start following companies at Redeye to receive the latest equity research within Life

Magnus Nilsson hands over the baton to Dag Andersson as President and CEO of XVIVO Perfusion

Magnus Nilsson will hand over the baton to Dag Andersson as CEO of XVIVO Perfusion on June 1, 2020. At the same time Magnus Nilsson will remain as Senior Advisor to primarily work with R&D.XVIVO Perfusion AB's ("XVIVO") Board of Directors has decided to appoint Dag Andersson, 58, as President and CEO of XVIVO. Dag Andersson takes up his new position on June 1, 2020. Dag has a background in biotechnology as CEO of Diaverum AB from 2008 up until 2018 and before that worked for 15 years in leading roles in Mölnlycke Health Care. He holds an MBA from INSEAD and a BA (Hons) in Business and

Strong cash flow despite the influence of Covid-19

FIRST QUARTER 2020 (JAN - MAR)· Total net sales (incl. durable goods) in the quarter amounted to SEK 46.5 (47.7) million, corresponding to a decrease of 3 percent in SEK and 6 percent in local currency. Net sales of non-durable goods in the quarter amounted to SEK 44.2 (46.8) million, corresponding to a decrease of 6 percent in SEK and 9 percent in local currency. · Sales from warm perfusion represented 27 percent (43) of sales of non-durable goods. Sales of warm perfusion products were affected in March partly due to fewer EVLP:s being performed and partly because some orders were not

Conference call on Interim Report (link updated)

Invitation to attend XVIVO Perfusion’s conference call regarding the presentation of the interim report January - March 2020. The presentation will be held in English. Link to registration updated.Time: Thursday, April 9, 2020 at 11.30 a.m. CET Information regarding the conference can be found under the following link:https://onlinexperiences.com/Launch/QReg/ShowUUID=814D6CAF-DC4B-424B-9625-B9B7E6A03FB3 Phone numbers to the conference:Sweden dial in number: +46 856 642 651 USA dial in number: +1 631 913 1422 International (UK) dial in number: +44 (0)3333 000 804

Report from Annual general meeting of XVIVO Perfusion AB (publ)

The following resolutions were amongst those adopted at XVIVO Perfusion’s Annual General Meeting held on March 31, 2020: • No dividend will be paid for the financial year 2019. • Gösta Johannesson, Camilla Öberg, Folke Nilsson, Yvonne Mårtensson and Dag Andersson were re-elected as members of the Board and Gösta Johannesson was elected Chairman of the Board, all in accordance with the proposal of the Election Committee. KPMG was elected as the company's auditor with Jan Malm as principal auditor until the end of the AGM for the financial year 2020. • Board remuneration were

XPS™ sold to pediatric transplantation clinic in Italy

A pediatric transplantation clinic in Rome, Italy, has purchased an XPS™. This is the first XPS ™ for a pediatric hospital which will enable more transplants for children and adolescents with terminal lung disease.There are approximately 200 lung transplants performed every year in Italy, whereof today only a few are pediatric lung transplants. The most common indication for lung transplantation in children is Cystic Fibrosis, a genetic disorder that causes thick mucus in the lungs. Clinics in Italy have been among the first to use EVLP to increase the proportion of lungs for

The Nomination Committee proposes unchanged Board remuneration -adjusted version

Due to the situation with the corona pandemic, XVIVO Perfusion's Nomination Committee, and the shareholders who have appointed the members in the Nomination Committee, has decided to withdraw the proposal that XVIVO Perfusion's Annual General Meeting on March 31, 2020 approves an increase in Board remuneration (item 12 on the agenda). Instead, the Nomination Committee, and the shareholders who have appointed the members in the Nomination Committee, proposes unchanged Board remuneration compared to 2019. The Nomination Committee's other proposals for the Annual General Meeting remain

The Nomination Committee proposes unchanged Board remuneration

Due to the situation with the corona pandemic, XVIVO Perfusion's Nomination Committee has decided to withdraw the proposal that XVIVO Perfusion's Annual General Meeting on March 31, 2020 approves an increase in Board remuneration (item 12 on the agenda). Instead, the Nomination Committee proposes unchanged Board remuneration compared to 2019. The Nomination Committee's other proposals for the Annual General Meeting remain unchanged.

As a result of Covid-19: The Annual General Meeting of XVIVO Perfusion is moved to a new address and further precautions are taken

As a precautionary measure to reduce the risk of spreading the new corona virus (Covid-19), the Board of Directors of XVIVO Perfusion AB has decided to move the Annual General Meeting to larger premises at the Svenska Mässan (conference room J1) at Mässans gata 24 in Gothenburg. The date and time for the Annual General Meeting will is still Tuesday, March 31 at. 15:00. In order to safeguard the participants' health, a further number of decisions have been made regarding the implementation of the company's annual general meeting. The goal is for the AGM to be short and effective to

THE COVID-19 EFFECT ON XVIVO PERFUSION

XVIVO Perfusion sees a decline in demand for transplant products due to the Covid-19 epidemic for at least the next quarter but sees no long-term impact on demand. The planned start of the clinical trials in Europe has been delayed. An action program is now being implemented to reduce expenditure.The ongoing Covid-19 epidemic has already led to adjustments and restrictions for most businesses, which is also the case for transplants, especially in the countries most affected by the virus. This has had a negative impact on sales for XVIVO Perfusion during the first quarter. The company

Notice to attend the Annual General Meeting of XVIVO Perfusion AB (publ)

The shareholders of XVIVO Perfusion AB (publ), corporate identity number 556561-0424 (“the Company”), are hereby invited to attend the Annual General Meeting of shareholders on Tuesday March 31, 2020 at 15.00 at World Trade Center (Floor 7, one floor below the Company’s premises), Mässans gata 10 in Gothenburg, Sweden. Registration Shareholders who wish to attend the Annual General Meeting (AGM) must: - be entered in their own name (not through a nominee) in the register of shareholders maintained by Euroclear Sweden AB (“Euroclear”) on Wednesday March 25, 2020 and - notify

A historic year ended with a quarter of sales records

FOURTH QUARTER 2019 (OCT - DEC) ·  Net sales of non-durable goods in the quarter amounted to SEK 59.4 (52.3) million, corresponding to an increase of 14 percent in SEK and 6 percent in local currency. Total net sales (incl. durable goods) in the quarter amounted to SEK 62.4 (58.4) million, corresponding to an increase of 7 percent in SEK and 0 percent in local currency. · Net sales of non-durable goods in the quarter amounted to SEK 59.4 (52.3) million, corresponding to an increase of 14 percent in SEK and 6 percent in local currency. Total net sales (incl. durable goods) in the

Conference call on Report on Operations

Invitation to attend XVIVO Perfusion’s conference call regarding the presentation of the report on operations 2019. The presentation will be held in English.Time: Thursday, January 30, 2020 at 2.00 p.m. CET Registration can preferably be done in advance under the following link:https://event.on24.com/wcc/r/2171524/4CB8422A65F1D7CC587A95F1003036A4 or shortly before time of the conference starts on:Sweden dial in number: +46 (0) 85 664 2651 USA dial in number: +1 631 913 1422 International dial in number: +44 (0) 3333 000 804Conference name: XVIVO Perfusion, conference ID:

XVIVO Perfusion granted Breakthrough Device Designation from the FDA for the XVIVO Heart Preservation System

XVIVO Perfusion has been granted ‘Breakthrough Device Designation’ from the U.S. Food and Drug Administration (FDA) for the XVIVO Heart Preservation System (XHPS), indicated for the hypo-thermic non-ischemic perfusion of excised donor hearts for preservation prior to transplant. The Breakthrough Device Designation is intended to expedite the development and prioritize the review of certain medical devices that provide for more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions.The Center for Devices and Radiological Health (CDRH) of the

Third XPS™ sold in Australia

The Fiona Stanley Hospital in Perth, Western Australia has recently acquired an XPS from XVIVO Perfusion AB (publ). This acquisition now sees three of the four Australian hospitals participating in the adult heart and lung transplant program having access to an XPS to assist in performing EVLP (Ex Vivo Lung Perfusion).  The Fiona Stanley Hospital XPS was kindly donated by Conquer Cystic Fibrosis Inc and the Spinnaker Health Research Foundation.XVIVO Perfusion has sold an XPS to Fiona Stanley Hospital in Perth, Western Australia. Together with The Prince Charles Hospital, Brisbane and The

Good growth and new important XPS clinics

THIRD QUARTER 2019 (JULY - SEPTEMBER) · Net sales of non-durable goods in the quarter amounted to SEK 50.1 (40.3) million, corresponding to an increase of 25 percent in SEK and 18 percent in local currency. Total net sales (incl. durable goods) in the quarter amounted to SEK 54.3 (40.9) million, corresponding to an increase of 33 percent in SEK and 26 percent in local currency. · Sales from warm perfusion represented 42 percent (40) of sales of non-durable goods. · Operating income before depreciation and amortization (EBITDA) adjusted for costs for a share-based bonus program

XVIVO opens a subsidiary in Australia

Based on the increasing interest for XVIVO Perfusion´s products for lung transplantation as well as the high interest from all Australian clinics to participate in the Heart preservation study XVIVO Perfusion AB (publ) has decided to open a subsidiary in Sydney, Australia.   XVIVO also recently hired a Regional Business Manager with start date in October 2019.Currently XVIVO has two XPS-systems installed in the Pacific region and during the year the company noted an increasing interest from all five Lung transplant clinics to purchase an XPS. During the summer all heart transplant clinics

XVIVO Perfusion AB (publ) issue of warrants of series 2019/2021 fully subscribed

The annual general meeting in XVIVO Perfusion AB (publ) (”XVIVO”) on 25 April 2019 resolved to issue up to 351,000 share warrants of series 2019/2021 to employees of XVIVO and XVIVO’s Swedish subsidiaries, with a date of employment on or before 18 October 2019. A total of 351 000 warrants were subscribed which means that the issue has been subscribed in full.Each warrant entitles to subscribe for one new share in XVIVO for a subscription price corresponding to 150 percent of the volume weighted average price for XVIVO´s shares quoted on Nasdaq Stockholm for each trading day during (i) the

There are no items matching the current filter
There are no more items matching the current filter
Back to top